In brief
- The U.S. Department of Veterans Affairs (VA) has launched a randomized, placebo-controlled trial on MDMA-assisted therapy for veterans suffering from both PTSD and alcohol use disorder.
- Approximately 80 veterans will participate across two sites, Rhode Island and Connecticut, with results expected by 2030.
- The study joins 19 other active trials on psychedelic therapies within the veterans’ healthcare network, backed by over $23 million in external funding.
The U.S. Department of Veterans Affairs (VA) announced on May 26 the launch of a new clinical trial that combines MDMA with structured psychotherapy to simultaneously address post-traumatic stress disorder (PTSD) and problematic alcohol use in veterans. This represents one of the least explored diagnostic combinations in research involving this substance, which until now has primarily been studied for PTSD in isolation.
Trial design
The study, led by researcher Erica M. Eaton at the Providence VA Healthcare System (Rhode Island) with a second site at the VA Connecticut Healthcare System (West Haven), will recruit approximately 80 veterans. The design is randomized and active-placebo controlled: some participants will receive pharmaceutical-grade MDMA alongside psychotherapy sessions, while the control group will receive the same therapy structure accompanied by a placebo, with neither the evaluation team nor, as much as possible, the participants themselves knowing who is receiving which. Enrollment began on May 18, and results are not expected until 2030, which highlights the scale and methodological rigor of the follow-up.
Context: Funding and why now
The VA has allocated approximately $1.5 million to this specific study, part of a broader program that now includes 19 active trials on psychedelic therapies—with over $23 million in cumulative external funding—targeting various mental health issues among the veteran population. The move comes shortly after the FDA rejected the application for approval of MDMA therapy for PTSD submitted by Lykos Therapeutics in 2024, and coincides with a U.S. executive order aimed at accelerating research into treatments for severe mental illness. VA Secretary Doug Collins has described the trial as “an important step toward safely evaluating new approaches” for conditions that combine trauma and alcohol use, which are especially prevalent among combat veterans.
Implications
The fact that a public institution as large as the VA is directly funding and conducting MDMA trials—rather than relying solely on a pharmaceutical company—changes the landscape: it provides independent data, protocols open to public scrutiny, and a population (veterans with PTSD and associated alcohol use) that has been underrepresented in large phase 3 trials until now. It is best not to jump to conclusions: this is a trial that is just beginning, with results years away, focusing on a combination of diagnoses that adds complexity compared to previous studies centered only on PTSD. MDMA remains unapproved as a medication in the United States and the European Union; this type of controlled clinical research is precisely the path that allows for the generation of solid evidence regarding the contexts and safeguards under which it may have therapeutic utility.
Source
- U.S. Department of Veterans Affairs. VA launches MDMA-assisted mental health therapy trial. VA News, May 26, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
